Our technology. The proprietary EveliQure vaccine technology platform is based on a live attenuated Shigella vaccine strain able to induce broad protection against shigellosis due to targeted genetic mutations.The platform is amenable for the heterologous expression of diarrheal antigens and therefore can provide protective immunity against ...